From muscle to luxury, GM had it covered. But this dominance came with internal politics and fear of brand competition. Some ...

Only those who clear Phase I will be eligible to appear for Phase II. The shortlisting for Phase III, i.e., the Interview round, will be based on the total marks secured in Papers I, II, and III of ...

The Johor Motorsports Racing Corvette Z06 GT3.R. Locally ... As it stands, the team has only announced a GT World Challenge Asia program. The season begins at Sepang on April 11-13 with further ...

As they prepare to host Gujarat Titans in their first home game of this season, optimism is running high among the Royal Challengers Bengaluru faithful. After kicking out Chennai Super Kings for a ...

Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a 19.8% weight loss in a Phase III trial. The Boston-based ...

Need more context? The MCU is split into Phases, with the end of a Phase typically indicating a natural end to a story arc. The beginning of a Phase, therefore, signals the introduction of new ...

The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 ...

Health Canada’s approval enables 4Moving Biotech to initiate the INFLAM MOTION Phase 2a clinical trial The INFLAM MOTION trial serves as a proof-of-concept study for 4Moving Biotech’s flagship ...

Mural Oncology is discontinuing the development of nemvaleukin alfa in ovarian cancer after a Phase III trial failed to improve overall survival (OS) in platinum-resistant ovarian cancer (PROC ...

Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol. IMNN-001, the company’s lead candidate ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis based on positive findings from multiple Phase III trials.

Gain Therapeutics begins Phase 1b trial for GT-02287, aimed at treating Parkinson's disease. Interim results expected mid-2025. Gain Therapeutics, Inc. announced the initiation of dosing for the ...